Résultats de la recherche
10
Tout
Rechercher les filtres
Organisation
Dyadic International, Inc.
Dyadic Reports 2024 Year-End Financial Results and Business Updates
26 mars 2025 16h05 HE
|
Dyadic International, Inc.
Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024Up to $7.5 million in grants awarded from CEPI and Gates Foundation intended to...
Dyadic Announces Funding Award from CEPI to Use C1 to Accelerate Development of Protein-Based Vaccines
20 mars 2025 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., March 20, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient...
Dyadic to Report 2024 Full Year Financial Results and Host Conference call on Wednesday, March 26, 2025
12 mars 2025 16h00 HE
|
Dyadic International, Inc.
JUPITER, Fla., March 12, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company focused on the efficient...
Dyadic to Attend Multiple Industry Events in March
06 mars 2025 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company focused on the efficient...
Dyadic Provides Business Update; Dyadic to Attend the 43rd Annual J.P. Morgan Healthcare Conference
06 janv. 2025 08h30 HE
|
Dyadic International, Inc.
Dyadic Provides Business Update
Dyadic to Attend the
43rd Annual J.P. Morgan Healthcare Conference
Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology
21 nov. 2024 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ: DYAI), a global biotechnology company, announced today that it has been awarded a $3 million grant from the Gates...
Dyadic Announces Third Quarter 2024 Financial Results and Strategic Progress Across Key Markets
12 nov. 2024 16h05 HE
|
Dyadic International, Inc.
Highlights Revenue Milestones and Expands Alternative Protein & Pharmaceutical Partnerships with Dapibus™ & C1 Technology Platforms Alternative Proteins Demonstrated substantial revenue...
Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
04 nov. 2024 16h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient...
Dyadic Expands Global Presence with Participation in Key Industry Events
09 oct. 2024 08h00 HE
|
Dyadic International, Inc.
JUPITER, Fla., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the large-scale, efficient manufacturing of...
Dyadic Provides Alternative Proteins Business Update and Announces Attendance at Bioprocess International Conference
23 sept. 2024 09h50 HE
|
Dyadic International, Inc.
JUPITER, Fla., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient,...